BBIO

Bridgebio Pharma Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 0/10
  • Value↓ 0/10
Bridgebio Pharma sales and earnings growth
BBIO Growth
Low
  • Revenue Y/Y↑ 355.17%
  • EPS Y/Y↓ -5.07%
  • FCF Y/Y↑ 11.09%
Bridgebio Pharma gross and profit margin trends
BBIO Profitability
Good
  • Gross margin ↑ 95.10%
  • EPS margin↓ -124.40%
  • ROIC 5Y↓ -28.27%
Bridgebio Pharma net debt vs free cash flow
BBIO Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 3.6
  • Interest coverage↓ -8.7

Bridgebio Pharma stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks